Surfing the MASH Tsunami

Send us Fan Mail Next week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress (#ILC2022), the first meeting at this level since the pandemic started to include an in-person attendance option. This week, NASH Tsunami identifies some of the most important and intriguing non-embargoed presentations at #ILC2022. This conver...

Send us Fan Mail Next week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress (#ILC2022), the first meeting at this level since the pandemic started to include an in-person attendance option. This week, NASH Tsunami identifies some of the most important and intriguing non-embargoed presentations at #ILC2022. This conver...

Send us Fan Mail Next week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress (#ILC2022), the first meeting at this level since the pandemic started to include an in-person attendance option. This week, NASH Tsunami identifies some of the most important and intriguing non-embargoed presentations at #ILC2022. This conver...

Send us Fan Mail Next week, >10,000 Fatty Liver stakeholders are expected to journey to London (rail strike and all) for the International Liver Congress (#ILC2022), the first meeting at this level since the pandemic started to include an in-person attendance option. This week, NASH Tsunami identifies some of the most important and intriguing non-embargoed presentations at #ILC2022. This conver...

Send us Fan Mail This week, NASH Tsunami identifies some of the most important and intriguing presentations at next week's International Liver Congress (#ILC2022) meeting, many of which focus on NITs and patient issues, including quality of life (QoL). The group was free to discuss any presentation not under embargo, which precluded several major drug development presentations. Here are the p...

Send us Fan Mail Thursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. For the #NASHDay Wrap-up Panel, Global Liver Institute invited NASH Tsunami co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to join NASH Programs Director Jeff McIntyre to discuss theme...

Send us Fan Mail Thursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. For the #NASHDay Wrap-up Panel, Global Liver Institute invited NASH Tsunami co-hosts Jörn Schattenberg, Louise Campbell and Roger Green to join NASH Programs Director Jeff McIntyre to discuss theme...

Send us Fan Mail Thursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. To celebrate the occasion, Stephen Harrison joined Jörn Schattenberg, Louise Campbell and Roger Green to celebrate the event and comment on one crucial trend or event most signified what the last y...

Send us Fan Mail Thursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. To celebrate the occasion, Stephen Harrison joined Jörn Schattenberg, Louise Campbell and Roger Green to celebrate the event and comment on one crucial trend or event most signified what the last y...

Send us Fan Mail Thursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. To celebrate the occasion, Stephen Harrison joined Jörn Schattenberg, Louise Campbell and Roger Green to celebrate the event and comment on one crucial trend or event most signified what the last y...

Send us Fan Mail Thursday, June 9, marked #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. To celebrate the occasion, Stephen Harrison joined Jörn Schattenberg, Louise Campbell and Roger Green to celebrate the event and comment on one crucial trend or event most signified what the last y...

Send us Fan Mail Today, June 9, was the 5th International NASH Day (#NASHDay). Global Liver Institute (@GlobalLiver), the largest liver patient advocacy organization in the world, and 200 partner organizations held a day of education, awareness and motivation for Fatty Liver stakeholders the world around. For its wrap-up panel, GLI invited the SurfingNASH co-host team to sit with Jeff McIntyre and...

Send us Fan Mail Thursday, June 9, marks #NASHDay 2022, the 5th annual celebration of International NASH Day by the world's largest liver patient advocacy organization, the Global Liver Institute. With over 200 affiliated organizations and sponsors, many holding their own events, International NASH Day is not only a major day for education and communication, but also in a sense NASH's &q...

Send us Fan Mail On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD-related topics. This conversation includes two shorter interviews. In the first, Louise Campbell and Aged Diagnostics CEO Rachel Zayas interview Altimmune Chief Medical Officer Scott Harris about dual agonist weight loss agents. In the second, Rachel interviews An...

Send us Fan Mail On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD-related topics. In this conversation, Louise Campbell interviews Julius Clinical Chief Scientific Officer Diederick (Rick) Grobbee about NAFLD screening in primary care practices as exemplified in Julius's GRIP Program. Most of this conversation centered arou...

Send us Fan Mail On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD topics. In this conversation, Aged Diagnostics CEO Rachel Zayas, who attended the conference for Surfing the NASH Tsunami, interviews Madrigal Pharmaceuticals Founder, Chief Medical Officer and President of R & D Rebecca (Becky) Taub. Becky Taub's talk at...

Send us Fan Mail On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of NAFLD topics. In this conversation, Louise Campbell and Rachel Zayas, who attended the conference for Surfing the NASH Tsunami, discuss what they considered the most important and interesting presentations at the Congress. This fast-moving conversation touches on a rang...

Send us Fan Mail On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of topics related to Fatty Liver disease. In this conversation, Louise Campbell, who attended the conference for Surfing the NASH Tsunami, discusses presentations she found of particular interest. Jörn Schattenberg and Roger Green, who did not attend, ask questions about t...

Send us Fan Mail On May 27 and 28, Surfing the NASH Tsunami covered the 5th Global NASH Congress, which discussed a wide range of topics related to Fatty Liver disease. In this conversation, Louise Campbell, who attended the conference for Surfing the NASH Tsunami, discusses presentations she found of particular interest. Jörn Schattenberg and Roger Green, who did not attend, ask questions about t...

Send us Fan Mail Surfing the NASH Tsunami covered the 5th Global NASH Congress. Louise Campbell and Rachel Zayas conducted speaker interviews with executives from Madrigal Pharmaceuticals, Altimmune, Antaros Medical and Julius Clinical, and the Surfers shared reflections on meeting topics and other key Fatty Liver-related issues. This episode blends conversations between the Surfers and "Surf...

Send us Fan Mail his conversation ties up some of the loose ends of the broader "stacking" issue. Quentin Anstee addresses Roger Green's earlier concern about whether stacking variables would magnify statistical error by suggesting that if the goal of stacking is to amplify a "ground truth", this should not imply greater error. Louise Campbell asks about future prediction...

Send us Fan Mail This conversation starts with Roger Green asking Quentin Anstee to clarify exactly what he means by "stacking" variables. Quentin's reply: multiple measures to confirm the same endpoint or result, so that the more measure achieve the target, the more confident we can be that therapy has succeeded.  Louise Campbell suggests that this kind of stacking approach might e...

Send us Fan Mail This conversation starts with Quentin Anstee complimenting Stephen Harrison for his observation that when we analyze NASH Biomarkers, we should consider the value of sustained response separate from early OR late response. From here, the group moves to the concept of "stacked" tests -- confirmatory results from different NITs as a way to assess efficacy in an individual...

Send us Fan Mail This conversation starts with Quentin Anstee sharing the five key takeaways for NITs in general and NIT Best Practices he developed while preparing recent talks for the Liver Forum and the ICFL meeting in Vienna: (1) As we have discussed on this podcast and elsewhere, trial endpoints around balloon hepatocytes are, in Quentin's words, "not sufficiently robust." (2)...

Send us Fan Mail Quentin Anstee joins Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green to share recently developed insights about NITs and what the clinical trial best practices around them should be. Quentin started by offer five key takeaways from his recent talks at The Liver Forum and ICFL in Vienna: (1) As we have discussed on this podcast and elsewhere, trial endpoints ar...